The use of TNF-α antagonist (infliximab) was found effective in inducing and prolonging remission in children with IBD, helping in mucosal healing in this population, and reversing growth failure in children with severe refractory CD [103]. This evidence concerns the gene TNF and inflammatory bowel disease.